Cargando…
EP4 Antagonism by E7046 diminishes Myeloid immunosuppression and synergizes with Treg-reducing IL-2-Diphtheria toxin fusion protein in restoring anti-tumor immunity
Reprogramming of immunosuppressive tumor microenvironment (TME) by targeting alternatively activated tumor associated macrophages (M2TAM), myeloid-derived suppressor cells (MDSC), and regulatory T cells (Tregs), represents a promising strategy for developing novel cancer immunotherapy. Prostaglandin...
Autores principales: | Albu, Diana I., Wang, Zichun, Huang, Kuan-Chun, Wu, Jiayi, Twine, Natalie, Leacu, Sarah, Ingersoll, Christy, Parent, Lana, Lee, Winnie, Liu, Diana, Wright-Michaud, Renee, Kumar, Namita, Kuznetsov, Galina, Chen, Qian, Zheng, Wanjun, Nomoto, Kenichi, Woodall-Jappe, Mary, Bao, Xingfeng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593700/ https://www.ncbi.nlm.nih.gov/pubmed/28920002 http://dx.doi.org/10.1080/2162402X.2017.1338239 |
Ejemplares similares
-
Combination of EP4 antagonist and checkpoint inhibitors promotes anti-tumor effector T cells in preclinical tumor models
por: Bao, Xingfeng, et al.
Publicado: (2015) -
High-Temperature Compression Behaviors and Constitutive Models of a 7046-Aluminum Alloy
por: He, Daoguang, et al.
Publicado: (2023) -
First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE(2)-receptor E-type 4 (EP4), in patients with advanced cancers
por: Hong, David S, et al.
Publicado: (2020) -
Can the Period of Infectiveness of Diphtheria Be Shortened and Its Tendency to Spread Diminished?
por: Ewart, Wm.
Publicado: (1900) -
Targeting regulatory T cells by E7777 enhances CD8 T-cell–mediated anti-tumor activity and extends survival benefit of anti-PD-1 in solid tumor models
por: Mahdi, Haider S., et al.
Publicado: (2023)